Update shared on30 Jul 2025
Fair value Increased 43%The notable upward revision in Claritev’s consensus price target appears driven by a significant increase in its future P/E multiple despite a modest decline in net profit margin, resulting in a new fair value estimate of $47.00.
What's in the News
- Claritev was added to several Russell indices, including Russell 2000, 2500, 3000, Microcap, and related growth/sector benchmarks, enhancing index weighting and potential passive inflows.
- Announced collaboration with Fractional AI to advance its generative AI strategy, aiming for innovation and responsible adoption in healthcare AI initiatives.
- Joined the Coalition for Health AI to help develop best practices and frameworks for responsible AI development and deployment in healthcare.
- Formalized a strategic relationship with Claims Care Revenue Cycle Management to expand into the MENA region and improve healthcare affordability, transparency, and efficiency through AI-driven solutions.
- Entered strategic partnerships with Lantern and Great Speech to optimize healthcare costs and expand access to high-quality virtual speech therapy through Claritev’s networks.
Valuation Changes
Summary of Valuation Changes for Claritev
- The Consensus Analyst Price Target has significantly risen from $34.50 to $47.00.
- The Future P/E for Claritev has significantly risen from 5.63x to 7.84x.
- The Net Profit Margin for Claritev has fallen slightly from 14.39% to 14.07%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.